KR20030016239A - 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물 - Google Patents

녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물 Download PDF

Info

Publication number
KR20030016239A
KR20030016239A KR1020027012169A KR20027012169A KR20030016239A KR 20030016239 A KR20030016239 A KR 20030016239A KR 1020027012169 A KR1020027012169 A KR 1020027012169A KR 20027012169 A KR20027012169 A KR 20027012169A KR 20030016239 A KR20030016239 A KR 20030016239A
Authority
KR
South Korea
Prior art keywords
aminopropyl
compound
compounds
methyl
iop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020027012169A
Other languages
English (en)
Korean (ko)
Inventor
로버트 제이. 주니어 콜리어
토마스 알. 딘
마크 알. 헬베르그
Original Assignee
알콘, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘, 인코퍼레이티드 filed Critical 알콘, 인코퍼레이티드
Publication of KR20030016239A publication Critical patent/KR20030016239A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
KR1020027012169A 2000-03-17 2001-02-20 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물 Withdrawn KR20030016239A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
US60/190,279 2000-03-17

Publications (1)

Publication Number Publication Date
KR20030016239A true KR20030016239A (ko) 2003-02-26

Family

ID=22700682

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020027012169A Withdrawn KR20030016239A (ko) 2000-03-17 2001-02-20 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물
KR1020027012171A Withdrawn KR20030009390A (ko) 2000-03-17 2001-02-23 시야 감소를 억제하는데 유용한 5-ｈｔ 활성을 갖는화합물
KR1020027012170A Expired - Fee Related KR100749191B1 (ko) 2000-03-17 2001-02-23 외망막의 질환을 치료하기에 유용한 ５－ｈｔ１ａ 활성을 가진 화합물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020027012171A Withdrawn KR20030009390A (ko) 2000-03-17 2001-02-23 시야 감소를 억제하는데 유용한 5-ｈｔ 활성을 갖는화합물
KR1020027012170A Expired - Fee Related KR100749191B1 (ko) 2000-03-17 2001-02-23 외망막의 질환을 치료하기에 유용한 ５－ｈｔ１ａ 활성을 가진 화합물

Country Status (18)

Country Link
EP (3) EP1263434A1 (enExample)
JP (5) JP2003527423A (enExample)
KR (3) KR20030016239A (enExample)
CN (2) CN1418100A (enExample)
AR (1) AR028258A1 (enExample)
AT (1) ATE247507T1 (enExample)
AU (5) AU2001238552A1 (enExample)
BR (3) BR0109193A (enExample)
CA (3) CA2400637A1 (enExample)
DE (1) DE60100625T2 (enExample)
DK (1) DK1263504T3 (enExample)
ES (1) ES2204848T3 (enExample)
MX (3) MXPA02009071A (enExample)
PL (1) PL203709B1 (enExample)
PT (1) PT1263504E (enExample)
TW (1) TWI268777B (enExample)
WO (3) WO2001070223A1 (enExample)
ZA (1) ZA200206350B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
EP1263434A1 (en) * 2000-03-17 2002-12-11 Alcon, Inc Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
CA2520813C (en) * 2003-04-25 2009-10-27 Mitsubishi Pharma Corporation Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CA3130770A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
KR20210134928A (ko) 2019-02-27 2021-11-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 n-치환된 인돌 및 다른 헤테로사이클
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
JP2024546180A (ja) * 2021-12-23 2024-12-17 シルケア ディーイーヴィ 聴覚疾患の治療のための４－フェニル－テトラヒドロピリジン誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
EP1263434A1 (en) * 2000-03-17 2002-12-11 Alcon, Inc Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma

Also Published As

Publication number Publication date
KR20020082885A (ko) 2002-10-31
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
MXPA02009071A (es) 2003-05-23
PL203709B1 (pl) 2009-11-30
HK1051504A1 (en) 2003-08-08
AU2005202600B2 (en) 2008-07-31
AR028258A1 (es) 2003-04-30
KR100749191B1 (ko) 2007-08-13
MXPA02009072A (es) 2003-03-12
DE60100625D1 (de) 2003-09-25
CN1198605C (zh) 2005-04-27
CN1418121A (zh) 2003-05-14
DK1263504T3 (da) 2003-12-08
EP1263504A2 (en) 2002-12-11
BR0109230A (pt) 2003-06-03
PT1263504E (pt) 2003-12-31
CA2400639C (en) 2011-08-16
JP2003527423A (ja) 2003-09-16
CN1418100A (zh) 2003-05-14
ZA200206350B (en) 2003-08-08
CA2400639A1 (en) 2001-09-27
CA2399985A1 (en) 2001-09-27
WO2001070222A2 (en) 2001-09-27
DE60100625T2 (de) 2004-02-26
EP1263504B1 (en) 2003-08-20
WO2001070222A3 (en) 2002-07-25
JP4789231B2 (ja) 2011-10-12
JP2011037901A (ja) 2011-02-24
ES2204848T3 (es) 2004-05-01
JP2003527422A (ja) 2003-09-16
WO2001070230A2 (en) 2001-09-27
BR0109193A (pt) 2003-05-27
WO2001070223A1 (en) 2001-09-27
JP2011153158A (ja) 2011-08-11
PL358306A1 (en) 2004-08-09
JP2003527427A (ja) 2003-09-16
CA2400637A1 (en) 2001-09-27
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
AU4531001A (en) 2001-10-03
TWI268777B (en) 2006-12-21
KR20030009390A (ko) 2003-01-29
MXPA02009073A (es) 2003-03-12
AU2001239836A1 (en) 2001-10-03
ATE247507T1 (de) 2003-09-15
EP1263434A1 (en) 2002-12-11
EP1267878A2 (en) 2003-01-02
WO2001070230A3 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
KR20030016239A (ko) 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물
US6664286B1 (en) Serotonergic 5ht2 agonists for treating glaucoma
EP2156833B1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
JP2007217437A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
US20100168121A1 (en) Compounds with 5-ht1a activity useful for treating disorders of the outer retina
EP1169061A1 (en) Combination therapy for treating glaucoma
KR100499903B1 (ko) 안압 제어 및 녹내장 치료용 5ｈｔ2 효능제
KR20040068315A (ko) 벤조디푸란이미다졸린 및 벤조푸란이미다졸린 유도체 및녹내장 치료를 위한 이들의 용도
US20030114512A1 (en) Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
WO2003051291A2 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
US20030119846A1 (en) Compounds with 5-ht activity useful for controlling visual field loss
US20060211700A1 (en) (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma
KR20010024889A (ko) 시신경유두 순환 개선제
AU2004214563A1 (en) Combination therapy for treating glaucoma
Alm et al. A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability in the Management of Primary Open-Angle Glaucoma and Ocular Hypertension
HK1051504B (en) Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020916

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid